Treatment of E. coli Infections
For uncomplicated lower urinary tract infections caused by E. coli, use amoxicillin-clavulanic acid, nitrofurantoin, or sulfamethoxazole-trimethoprim as first-line therapy 1.
Lower Urinary Tract Infections (Cystitis)
The WHO Expert Committee specifically recommends three Access-category antibiotics as first-choice options 1:
- Amoxicillin-clavulanic acid
- Nitrofurantoin
- Sulfamethoxazole-trimethoprim
Critical Context on Antibiotic Selection
Plain amoxicillin was removed from recommendations in 2021 after GLASS surveillance data showed 75% median resistance among E. coli urinary isolates globally (range 45-100%) 1. This is a crucial pitfall to avoid—do not use amoxicillin monotherapy for empiric treatment of E. coli UTIs.
Avoid fluoroquinolones (ciprofloxacin, levofloxacin) for uncomplicated cystitis due to high resistance rates and FDA warnings about serious adverse effects on tendons, muscles, joints, nerves, and the central nervous system 1, 2. Recent data shows only 21.9% susceptibility to levofloxacin in E. coli urinary isolates 2.
Fosfomycin, while having minimal resistance and good safety profile, was not recommended by the WHO Expert Committee for lower UTI despite Working Group proposals 1.
Upper Urinary Tract Infections (Pyelonephritis/Prostatitis)
Mild-to-Moderate Disease
Ciprofloxacin is the first-choice option, but only if local antimicrobial resistance data support its use 1. Given the FDA safety warnings, reserve fluoroquinolones for situations where benefits outweigh risks.
Alternative: Ceftriaxone or cefotaxime (Watch category) 1
Severe Disease
First-line: Ceftriaxone or cefotaxime 1
Second-line: Amikacin (preferred over gentamicin due to better activity against Enterobacterales, including ESBL-producers) 1
Multidrug-Resistant (MDR) E. coli
For ESBL-producing E. coli (the most common MDR mechanism), treatment options narrow significantly 3, 4:
Oral Options for ESBL-E. coli UTIs:
- Nitrofurantoin
- Fosfomycin
- Pivmecillinam
- Amoxicillin-clavulanate (for ESBL-E. coli only, not ESBL-Klebsiella)
Parenteral Options for ESBL-E. coli:
- Carbapenems (ertapenem, imipenem, meropenem) remain the mainstay—susceptibility data shows 99.3% sensitivity 2, 4
- Piperacillin-tazobactam (92.3% susceptibility) 2
- Cefepime (76.3% susceptibility) 2
- Aminoglycosides: amikacin (98.3% susceptibility) 2
Carbapenem-Resistant E. coli:
This represents the most challenging scenario. Options include 4, 5:
- Ceftazidime-avibactam
- Meropenem-vaborbactam
- Imipenem-cilastatin-relebactam
- Cefiderocol
- For metallo-β-lactamase producers (NDM, IMP-4): ceftazidime-avibactam plus aztreonam combination 4
Special Populations
Pregnancy
Use cephalosporins (e.g., cefuroxime) or nitrofurantoin 6. Avoid fluoroquinolones and trimethoprim in first trimester.
Pediatric Bacteremia
For infants with E. coli bacteremia without CSF evaluation, treat for at least 14 days, with consideration of 21-day courses to reduce mortality and recurrence risk 7.
Key Clinical Pitfalls
- Do not use amoxicillin monotherapy—resistance exceeds 75% globally 1
- Avoid empiric fluoroquinolones for simple cystitis—reserve for pyelonephritis when resistance patterns allow 1, 2
- Second-generation cephalosporins are not recommended for empiric therapy—only 56.6% susceptibility to cefuroxime 2
- Hospital-acquired infections require different considerations—predominantly ESBL-positive with longer hospitalization 2
- Community-acquired infections are mostly ESBL-negative, making third-generation cephalosporins still viable 2
Treatment Duration
- Uncomplicated cystitis: 5 days for nitrofurantoin, single dose for fosfomycin 5
- Pyelonephritis: Typically 7-14 days depending on severity
- Bacteremia in infants: Minimum 14 days, consider 21 days 7
The evidence strongly supports de-escalation based on culture results and clinical response rather than prolonged broad-spectrum empiric therapy, which reduces hospitalization and resistance development 2.